logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Neurocrine Biosciences, Inc.


USPTO Granted Patents = 120



Trademarks = 43

Forward Citations = 679

Loading Chart...
Loading Chart...

131 inventors (with patents filed for the assignee):

goldMedal Chen Chen (23 out of 34 patents)

silverMedal Zhiqiang Guo (22 out of 25 patents)

bronzeMedal Neil Ashweek (19 out of 24 patents)

4.  Martin W Rowbottom (19 out of 41 patents)

5.  Yun-Fei Zhu (18 out of 18 patents)

6.  Warren Stanfield Wade (16 out of 32 patents)

7.  Charles Q Huang (14 out of 19 patents)

8.  James R McCarthy (12 out of 79 patents)

9.  Dongpei Wu (11 out of 18 patents)

10.  Timothy Richard Coon (11 out of 26 patents)

11.  Christopher F O'Brien (11 out of 12 patents)

12.  Graham Beaton (10 out of 11 patents)

13.  Fabio C Tucci (10 out of 20 patents)

14.  Todd Ewing (9 out of 23 patents)

15.  Haig P Bozigian (9 out of 9 patents)


Core Competencies:
Muscarinic Receptor Antagonists
GPR52 Modulators
CRF Receptor Antagonists
VMAT2 Inhibitors
Gonadotropin-Releasing Hormone Receptor Antagonists
Pharmaceutical Formulations
Congenital Adrenal Hyperplasia Treatment
Synthetic Methods
Substituted Triazoles
Uracil Derivatives
High Dosage Valbenazine
Neurological Diseases

120 patents:

1. 12486250 - Muscarinic receptor 4 antagonists and methods of use (2025-12-02),
2. 12421193 - GPR52 modulators and methods of use (2025-09-23),
3. 12383536 - CRF receptor antagonists and methods of use (2025-08-12),
4. 12128033 - Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine (2024-10-29),
5. 12102637 - Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis (2024-10-01),
6. 12083227 - Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis (2024-09-10),
7. 11730739 - Treatment of congenital adrenal hyperplasia (2023-08-22),
8. 11718618 - Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors (2023-08-08),
9. 11713324 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto (2023-08-01),
10. 11654142 - Methods for the administration of certain VMAT2 inhibitors (2023-05-23),
11. 11459305 - Processes for the preparation of uracil derivatives (2022-10-04),
12. 11439629 - Methods for the administration of certain VMAT2 inhibitors (2022-09-13),
13. 11311544 - Treatment of congenital adrenal hyperplasia (2022-04-26),
14. 11311532 - High dosage valbenazine formulation and compositions, methods, and kits related thereto (2022-04-26),
15. 11053242 - [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto (2021-07-06),
Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company engaged in the discovery and development of innovative therapies for neurological and endocrine-related disorders. With a commitment to improving patients' lives, Neurocrine Biosciences strives to advance science, deliver exceptional therapies, and establish collaborations to address unmet medical needs in the field of neuroscience.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

...
120 Patents

#47 in San Diego, CA

#717 in California

#3,089 in US

#6,454 in the World

...
San Diego, CA, United States of America

Neurocrine Biosciences, Inc.

Forward Citations = 679

131 inventors:

goldMedal Chen Chen (23 out of 34 patents)

silverMedal Zhiqiang Guo (22 out of 25 patents)

bronzeMedal Neil Ashweek (19 out of 24 patents)

4.  Martin W Rowbottom (19 out of 41 patents)

5.  Yun-Fei Zhu (18 out of 18 patents)

Please report any incorrect information to support@idiyas.com
Loading…